Market Closed -
Hong Kong S.E.
04:08:07 2024-05-09 am EDT
|
5-day change
|
1st Jan Change
|
32.3
HKD
|
+1.10%
|
|
+15.56%
|
-13.75%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
39,166
|
31,092
|
36,877
|
28,299
|
25,502
|
-
|
-
|
Enterprise Value (EV)
1 |
36,595
|
29,387
|
34,808
|
28,741
|
26,371
|
27,157
|
28,053
|
P/E ratio
|
-56.1
x
|
111
x
|
-27.2
x
|
-11.9
x
|
-14.2
x
|
-23.7
x
|
-78.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
21.8
x
|
48
x
|
26.1
x
|
14.8
x
|
9.79
x
|
7.64
x
|
EV / Revenue
|
-
|
20.6
x
|
45.3
x
|
26.5
x
|
15.4
x
|
10.4
x
|
8.4
x
|
EV / EBITDA
|
-60.4
x
|
80.3
x
|
-43.8
x
|
-21.7
x
|
-29
x
|
-65.6
x
|
207
x
|
EV / FCF
|
-33.2
x
|
-83.6
x
|
-17.2
x
|
-12.2
x
|
-19.8
x
|
-39.2
x
|
-194
x
|
FCF Yield
|
-3.02%
|
-1.2%
|
-5.8%
|
-8.2%
|
-5.06%
|
-2.55%
|
-0.52%
|
Price to Book
|
10.9
x
|
8.98
x
|
3.64
x
|
5.34
x
|
5.65
x
|
6.72
x
|
8.4
x
|
Nbr of stocks (in thousands)
|
489,837
|
489,837
|
539,197
|
538,532
|
537,914
|
-
|
-
|
Reference price
2 |
79.96
|
63.47
|
51.14
|
34.04
|
29.86
|
29.86
|
29.86
|
Announcement Date
|
3/26/21
|
2/20/22
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
1,426
|
767.8
|
1,083
|
1,718
|
2,605
|
3,340
|
EBITDA
1 |
-
|
-605.6
|
365.8
|
-794.1
|
-1,322
|
-908.8
|
-414
|
135.4
|
EBIT
1 |
-
|
-668.6
|
281.6
|
-980.9
|
-1,502
|
-938.1
|
-250.3
|
99
|
Operating Margin
|
-
|
-
|
19.74%
|
-127.76%
|
-138.65%
|
-54.61%
|
-9.61%
|
2.96%
|
Earnings before Tax (EBT)
1 |
-
|
-697.8
|
276.3
|
-998.8
|
-1,511
|
-1,142
|
-687.3
|
-221.1
|
Net income
1 |
-430.3
|
-697.8
|
276.3
|
-998.8
|
-1,511
|
-1,138
|
-688.9
|
-216.7
|
Net margin
|
-
|
-
|
19.37%
|
-130.09%
|
-139.55%
|
-66.22%
|
-26.45%
|
-6.49%
|
EPS
2 |
-
|
-1.425
|
0.5700
|
-1.880
|
-2.860
|
-2.096
|
-1.258
|
-0.3809
|
Free Cash Flow
1 |
-
|
-1,104
|
-351.4
|
-2,019
|
-2,356
|
-1,335
|
-692
|
-144.8
|
FCF margin
|
-
|
-
|
-24.64%
|
-263%
|
-217.51%
|
-77.71%
|
-26.57%
|
-4.33%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/28/20
|
3/26/21
|
2/20/22
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 S1
|
2021 S2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
---|
Net sales
|
-
|
1,397
|
-
|
-
|
198.1
|
419
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
720.3
|
-
|
-
|
-
|
-509.7
|
-
|
Net income
1 |
-444
|
-
|
-489.1
|
-199.1
|
-
|
-509.7
|
-323.8
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-121.65%
|
-
|
EPS
2 |
-0.9100
|
-
|
-0.9600
|
-0.3600
|
-
|
-
|
-0.6000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/23/21
|
2/20/22
|
8/30/22
|
10/27/22
|
2/27/23
|
2/27/23
|
4/27/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
442
|
869
|
1,655
|
2,551
|
Net Cash position
1 |
-
|
2,571
|
1,704
|
2,069
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.3342
x
|
-0.9558
x
|
-3.996
x
|
18.85
x
|
Free Cash Flow
1 |
-
|
-1,104
|
-351
|
-2,019
|
-2,356
|
-1,335
|
-692
|
-145
|
ROE (net income / shareholders' equity)
|
-
|
-41.5%
|
7.85%
|
-23.7%
|
-35.5%
|
-38.6%
|
-34.8%
|
-21.6%
|
ROA (Net income/ Total Assets)
|
-
|
-29%
|
6.68%
|
-19.6%
|
-26.2%
|
-19.9%
|
-11.9%
|
-6.48%
|
Assets
1 |
-
|
2,403
|
4,138
|
5,090
|
5,775
|
5,719
|
5,803
|
3,342
|
Book Value Per Share
2 |
-
|
7.340
|
7.070
|
14.00
|
6.380
|
5.290
|
4.450
|
3.560
|
Cash Flow per Share
2 |
-
|
-1.620
|
0.5400
|
-2.380
|
-
|
-1.740
|
-0.5100
|
-0.1000
|
Capex
1 |
-
|
443
|
615
|
756
|
853
|
449
|
322
|
245
|
Capex / Sales
|
-
|
-
|
43.12%
|
98.41%
|
78.74%
|
26.13%
|
12.35%
|
7.32%
|
Announcement Date
|
10/28/20
|
3/26/21
|
2/20/22
|
2/27/23
|
2/23/24
|
-
|
-
|
-
|
Last Close Price
29.84
CNY Average target price
38.75
CNY Spread / Average Target +29.84% Consensus |
1st Jan change
|
Capi.
|
---|
| -13.75% | 3.55B | | +2.94% | 108B | | +10.30% | 105B | | +1.57% | 23.46B | | -12.53% | 21.72B | | -7.05% | 18.64B | | -37.64% | 17.45B | | -7.58% | 17.19B | | +5.92% | 13.99B | | +37.66% | 12.53B |
Bio Therapeutic Drugs
|